Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart

Trial Profile

Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Demyelinating disorders; Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms PROCEED
  • Sponsors Merck KGaA
  • Most Recent Events

    • 09 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 07 Dec 2015 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 07 Dec 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top